Patents Assigned to Cytopharm, Inc.
  • Patent number: 6107326
    Abstract: Cationic porphycenes are conjugated, through a carboxylic-acid bearing moiety, with polylysine through an amide linkage. The novel porphycenes are effective in treating microbial populations in vitro or in vivo and topically as well as for sterilizing articles.
    Type: Grant
    Filed: April 12, 1999
    Date of Patent: August 22, 2000
    Assignee: Cytopharm, Inc.
    Inventor: Giulio Jori
  • Patent number: 5756724
    Abstract: Coupling two moles of a 2-halopyrrole in the presence of an inert aromatic solvent and a catalytically effective amount of a substantially pure copper catalyst provides high yields of the corresponding bipyrrole.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: May 26, 1998
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Reiner Deponte
  • Patent number: 5637608
    Abstract: Novel 9-substituted porphycene compounds are useful in photodynamic therapy.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: June 10, 1997
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Martin Mueller, Otto Halpern, Alexander D. Cross
  • Patent number: 5610175
    Abstract: Porphycene compounds having the formula ##STR1## wherein each R is --(CH.sub.2).sub.n --X, n=1-10, X is OR.sup.1 and R.sup.1 is alkyl, aralkyl or aryl are useful as photosensitizer compounds in photodynamic therapy.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: March 11, 1997
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Martin Mueller, Otto Halpern, Alexander D. Cross
  • Patent number: 5409900
    Abstract: A porphycene having the structure ##STR1## wherein each R.sup.1 is, independently, (a) --(CH.sub.2).sub.n --X, where n=1-4, X is OR.sup.2 and R.sup.2 is C.sub.1-6 alkyl, aralkyl or aryl; CN; OH; OSO.sub.2 R.sup.2 ; NH.sub.2 ; NHR.sup.2 ; NR.sub.2.sup.2 ; SH; SR.sup.2 ; S(O).sub.1-2 R.sup.2 ; COOH; CO.sub.2 R.sup.2 ; C(O)NH.sub.2 ; C(O)NHR.sup.2 ; C(O)NR.sub.2.sup.2 ; halogen; or CHO;(b) --(CH.sub.2).sub.m CH.dbd.CH.sub.2 where m is 0-2; or(c) --(CH.sub.2).sub.n --O--G where G is a mono- or oligosaccharide;(d) --(CH.sub.2).sub.2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y-- (CH.sub.2).sub.n -porphycene.sup.2 (porphycene.sup.2 being a compound of the same structure and Y is a direct bond; --O--; or --CH.dbd.CH.sub.2); or(e) where one, two or three of the substituents R.sup.1 are C.sub.1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: April 25, 1995
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Clemens Richert, Thomas Benninghaus, Martin Muller, Alexander D. Cross
  • Patent number: 5262401
    Abstract: A porphycene having the structure ##STR1## wherein each R.sup.1 is, independently, (a) --(CH.sub.2).sub.n --X, where n= 1-4, X is OR.sup.2 and R.sup.2 is C.sub.1-6 alkyl, aralkyl or aryl; CN; OH; OSO.sub.2 R.sup.2 ; NH.sub.2 ; NHR.sup.2 ; NR.sup.2.sub.2 ; SH; SR.sup.2 ; S(O).sub.1-2 R.sup.2 ; COOH; CO.sub.2 R.sup.2 ; C(O)NH.sub.2 ; C(O)NHR.sup.2 ; C(O)NR.sup.2.sub.2 ; halogen; or CHO;(b) --(CH.sub.2).sub.m CH.dbd.CH.sub.2 where m is 0-2; or(c) --(CH.sub.2).sub.n --O--G where G is a mono- or oligosaccharide;(d) --(CH.sub.2).sub.2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y--(CH.sub.2).sub.n -porphycene.sup.2 (porphycene.sup.2 being a compound of the same structure and Y is a direct bond; --O--; or --CH.dbd.CH.sub.2); or(e) where one, two or three of the substituents R.sup.1 are C.sub.1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: November 16, 1993
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Clemens Richert, Thomas Benninghaus, Martin Muller, Alexander D. Cross
  • Patent number: 5244671
    Abstract: New porphycene compounds useful as photodynamic therapy agents. The porphycene compounds have an active group capable of binding to proteins and peptides and facilitating decomposition of the porphycenes following therapy.
    Type: Grant
    Filed: January 29, 1991
    Date of Patent: September 14, 1993
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Peter A. Koch, Afssaneh Rahbar, Alexander D. Cross
  • Patent number: 5179120
    Abstract: A porphycene having the structure ##STR1## wherein each R.sup.1 is, independently, (a) --(CH.sub.2).sub.n --X, where n=1-4, X is OR.sup.2 and R.sup.2 is C.sub.1-6 alkyl, aralkyl or aryl; CN; OH; OSO.sub.2 R.sup.2 ; NH.sub.2 ; NHR.sup.2 ; NR.sub.2.sup.2 ; SH; SR.sup.2 ; S(O).sub.1-2 R.sup.2 ; COOH; CO.sub.2 R.sup.2 ; C(O)NH.sub.2 ; C(O)NHR.sup.2 ; C(O)NR.sub.2.sup.2 ; halogen; or CHO;(b) --(CH.sub.2).sub.m CH.dbd.CH.sub.2 where m is 0-2; or(c) --(CH.sub.2).sub.n --O--G where G is a mono- or oligosaccharide;(d) --(CH.sub.2).sub.2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y--(CH.sub.2).sub.n -porphycene.sup.2 (porphycene.sup.2 being a compound of the same structure and Y is a direct bond; --O--; or --CH.dbd.CH.sub.2); or(e) where one, two or three of the substituents R.sup.1 are C.sub.1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof.
    Type: Grant
    Filed: June 28, 1991
    Date of Patent: January 12, 1993
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Clemens Richert, Thomas Benninghaus, Martin Muller, Alexander D. Cross
  • Patent number: 5132101
    Abstract: Dihydro- and tetrahydro-acetylene-cumulene porphycene compounds having the structure shown below ##STR1## are useful as photogynamic therapy agents.
    Type: Grant
    Filed: September 6, 1990
    Date of Patent: July 21, 1992
    Assignee: Cytopharm, Inc.
    Inventors: Emanuel Vogel, Alexander D. Cross, Norbert Jux, Eduardo Rodriguez-Val, Stefan Boehm, Wolfgang Hennig
  • Patent number: 5015478
    Abstract: The therapeutic compositions of this invention comprise one or more porphycene compounds incorporated within liposomes. The method of this invention for treating cancer comprises administering a therapeutically effective amount of a porphycene derivative to a patient, and exposing an affected body area of the patient to a therapeutically sufficient amount of light having a wavelength of from 600 to 950 nm.
    Type: Grant
    Filed: November 22, 1989
    Date of Patent: May 14, 1991
    Assignee: Cytopharm, Inc.
    Inventors: Giulio Jori, Matthias Kocher, Emanuel Vogel, Alexander D. Cross
  • Patent number: 4913907
    Abstract: The therapeutic compositions of this invention comprise one or more porphycene compounds incorporated within liposomes. The method of this invention for treating cancer comprises administering a therapeutically effective amount of a porphycene derivative to a patient, and exposing an affected body area of the patient to a therapeutically sufficient amount of light having a wavelength of from 600 to 950 nm.
    Type: Grant
    Filed: August 15, 1988
    Date of Patent: April 3, 1990
    Assignee: Cytopharm, Inc.
    Inventors: Giulio Jori, Matthias Kocher, Emanuel Vogel, Alexander D. Cross